Checchi Capital Advisers LLC Has $324,000 Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Checchi Capital Advisers LLC cut its position in Agilent Technologies, Inc. (NYSE:A) by 4.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,500 shares of the medical research company’s stock after selling 119 shares during the period. Checchi Capital Advisers LLC’s holdings in Agilent Technologies were worth $324,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Agilent Technologies by 18.2% in the first quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock valued at $4,348,471,000 after buying an additional 4,605,228 shares during the period. Norges Bank bought a new position in Agilent Technologies during the 4th quarter worth about $509,904,000. Massachusetts Financial Services Co. MA increased its holdings in Agilent Technologies by 19.6% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock worth $1,841,659,000 after purchasing an additional 2,170,219 shares in the last quarter. Brown Advisory Inc. raised its stake in shares of Agilent Technologies by 262.1% in the 4th quarter. Brown Advisory Inc. now owns 2,292,929 shares of the medical research company’s stock valued at $318,786,000 after purchasing an additional 1,659,768 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after buying an additional 1,042,926 shares during the period. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $141.09 on Thursday. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.35. The firm has a market capitalization of $41.16 billion, a P/E ratio of 33.35, a P/E/G ratio of 4.86 and a beta of 1.05. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.15 and a quick ratio of 1.64. The company’s 50 day moving average price is $134.46 and its two-hundred day moving average price is $138.70.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the firm posted $1.43 earnings per share. The firm’s revenue was down 5.6% compared to the same quarter last year. On average, equities analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,874 shares of company stock worth $2,811,770. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on A. Robert W. Baird cut their price target on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a research report on Thursday, May 30th. Wells Fargo & Company initiated coverage on Agilent Technologies in a report on Tuesday. They set an “overweight” rating and a $157.00 target price on the stock. Evercore ISI boosted their price target on Agilent Technologies from $130.00 to $135.00 and gave the stock an “in-line” rating in a research report on Thursday, August 22nd. JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $135.00 price target (down previously from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies presently has an average rating of “Moderate Buy” and an average price target of $141.60.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.